Resources
9 Results (showing 1 - 9)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 10/7/2019 (updated 3/25/2024)
Medication Assisted Treatment (MAT) for Opioid Use Disorder: Philosophical and Practical Considerations Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
The Adopting a Shared Framework for Community Collaboration webinar addresses new questions and comments about the development of a shared public health framework, strategic planning, consortium partners, and opioid use disorder treatment.
Posted 10/7/2019 (updated 3/25/2024)
Mapping Your Way from Vision to Impact: Strategic Planning Tools and Tips (Panel Discussion) Presentation and Resources.
Posted 12/30/2019 (updated 3/28/2024)
Pharmacotherapy of Opioid Use Disorder Webinar Presentation and Resources
Posted 5/27/2020 (updated 3/28/2024)
Materials from the Strategies for Engaging Your Community During the Pandemic webinar held on May 19, 2020 are below.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.